Key Stats for Recursion Pharmaceuticals Stock
- Price change for Recursion Pharmaceuticals stock: 13%
- $RXRX Stock Price as of Aug. 19: $4
- 52-Week High: $7
- $RXRX Stock Price Target: $7
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Recursion Pharmaceuticals (RXRX) stock jumped 13% on Wednesday after the company gave investors a mix of good news: real pipeline progress and tighter cost control.
Recursion Pharmaceuticals stock has been slowly climbing over the past few weeks, moving from around $3.00 to the $3.30 range in a steady, controlled pattern rather than a sudden spike, which traders often read as quiet accumulation instead of hype-driven buying.
On the financial side, the company posted a Q2 2026 loss of $0.25 per share, beating the $0.28 loss analysts at FactSet expected. Revenue came in at just $7.7 million, giving roughly a $131 million net loss for the quarter.
Still, the company holds about $545 million in cash, carries very little debt, and has a current ratio near 5, giving it plenty of room to keep funding its AI drug discovery work.
Management also cut full-year 2026 cash operating expense guidance by $15 million to about $375 million. That’s roughly 40% below 2024 spending levels, and the company now expects its cash to last into early 2028.
For a small-cap biotech that burns through cash quickly, that longer runway lowers the risk of a rushed, dilutive fundraising round.
On the pipeline front, Recursion highlighted progress on REC-4881, its treatment for FAP, along with REC-7735, an oncology asset now cleared to start Phase 1/2 trials in the second half of 2026.
The company also announced that Genentech moved its first neuroscience target into early discovery under their partnership, a sign that a major pharma partner sees real value in Recursion’s platform.
See analysts’ growth forecasts and price targets for Recursion Pharmaceuticals stock (It’s free) >>>
What the Market Is Telling Us About Recursion Pharmaceuticals Stock
The reaction shows investors prefer tangible progress over AI buzzwords.
When a partner like Genentech commits to developing a target, it works as outside validation of Recursion Pharmaceuticals stock’s technology, not just something from a company slide deck.
Wall Street’s view is mixed but generally positive. Morgan Stanley trimmed its price target from $5.50 to $5.30 while keeping an Equalweight rating, showing some caution about the company’s ongoing losses.
But the broader analyst group maintains an average Overweight rating with a consensus target of $7.22, well above where Recursion Pharmaceuticals stock currently trades.
That gap between the stock price and analyst targets is exactly the kind of setup that can create sharp price swings as new data and catalysts arrive.
With cash runway extended, spending under control, and multiple clinical catalysts on the calendar over the next year or two, the market appears willing to give Recursion Pharmaceuticals stock the benefit of the doubt for now.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Recursion Pharmaceuticals Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
